Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos

1285873

USP

Fluticasone propionate

United States Pharmacopeia (USP) Reference Standard

Sinônimo(s):

(6α,11β,16α,17α)-6,9-Difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic acid S-(fluoromethyl) ester

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C25H31F3O5S
Número CAS:
80474-14-2
Peso molecular:
500.57
Número MDL:
MFCD00866007
Código UNSPSC:
41116107
ID de substância PubChem:
329749903
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

fluticasone

fabricante/nome comercial

USP

aplicação(ões)

pharmaceutical (small molecule)

formato

neat

cadeia de caracteres SMILES

CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF

InChI

1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1

chave InChI

WMWTYOKRWGGJOA-CENSZEJFSA-N

Informações sobre genes

human ... NR3C1(2908)

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Fluticasone propionate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Fluticasone Propionate and Salmeterol Inhalation Aerosol®
  • Fluticasone Propionate and Salmeterol Inhalation Powder
  • Fluticasone Propionate Cream
  • Fluticasone Propionate Inhalation Aerosol®
  • Fluticasone Propionate Inhalation Powder
  • Fluticasone Propionate Lotion

Ações bioquímicas/fisiológicas

Fluticasone propionate is a second generation glucocorticoid. Used as an anti-inflammatory agent for asthma. Shown to enhance eosinophil apoptosis in a concentration-dependent manner via the glucocorticoid receptor.

Nota de análise

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Outras notas

Sales restrictions may apply.

Informações legais

Aerosol is a registered trademark of Cytec Technology Corp.

produto relacionado

Nº do produto
Descrição
Preços

Y0000284

Fluticasone propionate, European Pharmacopoeia (EP) Reference Standard

Y0000221

Fluticasone impurity D, European Pharmacopoeia (EP) Reference Standard

1285884

Fluticasone Propionate Resolution Mixture, United States Pharmacopeia (USP) Reference Standard

1285895

Fluticasone Propionate System Suitability Mixture, United States Pharmacopeia (USP) Reference Standard

1285840

Fluticasone Propionate Related Compounds Mixture, United States Pharmacopeia (USP) Reference Standard

1285910

Fluticasone Propionate Nasal Spray Resolution Mixture, United States Pharmacopeia (USP) Reference Standard

Y0001754

Fluticasone propionate for impurity C identification, European Pharmacopoeia (EP) Reference Standard

1285829

Fluticasone propionate Related Compound D, United States Pharmacopeia (USP) Reference Standard

1285818

Fluticasone propionate Related Compound J, United States Pharmacopeia (USP) Reference Standard

PHR1702

Fluticasone Propionate, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1844

Fluticasone Related Compound D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1842

Fluticasone Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1846

Fluticasone Related Compound J, Pharmaceutical Secondary Standard; Certified Reference Material

BP587

Fluticasone propionate, British Pharmacopoeia (BP) Reference Standard

BP588

Fluticasone S-methyl impurity, British Pharmacopoeia (BP) Reference Standard

Y0002249

Fluticasone propionate for system suitability, CRS, European Pharmacopoeia (EP) Reference Standard

PHR2270

Fluticasone Propionate Impurity A, certified reference material, pharmaceutical secondary standard

Pictogramas

Health hazard
GHS08

Palavra indicadora

Warning

Frases de perigo

H361f,H373

Classificações de perigo

Repr. 2 - STOT RE 2

Órgãos-alvo

Endocrine system

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Wei Liu et al.
Experimental and therapeutic medicine, 8(4), 1313-1317 (2014-09-05)
This study was designed to determine the expression of serum and sputum surfactant protein D (SP-D) in chronic obstructive pulmonary disease (COPD) and its association with treatment response. Sixty-five treatment-naive patients with COPD and 26 normal control subjects were recruited
M Berger et al.
Allergy, 70(3), 257-264 (2014-11-11)
House dust contains mite allergens as well as bacterial products such as lipopolysaccharide (LPS). Asthma exacerbations are associated with the level of exposure to allergens and LPS. LPS can potentiate allergen effects in steroid-naïve patients. Long-acting β2-agonists (LABA) were shown
T Welte et al.
International journal of clinical practice, 69(3), 336-349 (2014-11-05)
Chronic obstructive pulmonary disease (COPD) is usually a progressive condition. Undiagnosed early-stage disease, particularly in symptomatic patients, is likely to become more severe with time. Hence, prevention or reduction in disease progression is highly relevant. We evaluated the published data
Brian L Le et al.
Research square (2021-04-07)
The novel SARS-CoV-2 virus emerged in December 2019 and has few effective treatments. We applied a computational drug repositioning pipeline to SARS-CoV-2 differential gene expression signatures derived from publicly available data. We utilized three independent published studies to acquire or
Juliet M Foster et al.
The Journal of allergy and clinical immunology, 134(6), 1260-1268 (2014-07-27)
Poor adherence contributes to uncontrolled asthma. Pragmatic adherence interventions for primary care settings are lacking. To test the effectiveness of 2 brief general practitioner (GP)-delivered interventions for improving adherence and asthma control. In a 6-month cluster randomized 2 × 2
Exibir todos os documentos relacionados

Artigos

Fluticasone Propionate Assay by HPLC UV USP Monograph

Learn how the Purospher® STAR RP-18e Hibar® HPLC column meets the system suitability criteria outlined in the USP monograph for the fluticasone propionate assay.

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica